This trial is active, not recruiting.

Conditions purpura, thrombocytopenic, idiopathic, autoimmune thrombocytopenic purpura, purpura, thrombocytopenic, autoimmune
Treatment veltuzumab
Phase phase 1/phase 2
Sponsor Immunomedics, Inc.
Start date November 2007
End date December 2016
Trial size 66 participants
Trial identifier NCT00547066, IM-T-hA20-07


This trial will study different dose levels of hA20 (IMMU-106) to see if they are safe and effective for treating ITP.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
veltuzumab is a humanized CD20 antibody administered subcutaneously.
veltuzumab IMMU-106
hA20 will be administered intravenously in two doses over two weeks

Primary Outcomes

time frame: 1 year
time frame: 5 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Male or female, >18 years old, with or without prior splenectomy - Signed written informed consent obtained prior to study entry - ITP according to ASH guidelines, with other potential causes of thrombocytopenia excluded - Platelet levels < 150 x 109/L for more than 6 months - Received an adequate course of at least one standard ITP treatment (an inadequate course of standard ITP therapy does not qualify as meeting this requirement) - Platelet count < 30 x 109/L at study entry and on at least one other occasion at least 1 week apart within the past month. (Phase I only: platelet count also > 10 x 109/L at study entry). - Bleeding assessment score of Grade 0 or 1. See full protocol for all inclusion criteria Exclusion Criteria: See full protocol for exclusion criteria or contact study staff for details

Additional Information

Official title A Phase I/II Study of Immunotherapy With Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Adult Patients With Chronic Immune Thrombocytopenic Purpura
Description The goal of current treatment guidelines for most patients with chronic adult ITP is to maintain platelet levels above 30 x 109/L. The conventional first-line therapy is corticosteroids with or without intravenous immunoglobulins, but many patients relapse when steroids are tapered. Standard therapy then is splenectomy, but patients with refractory ITP who do not respond require further therapy. Unfortunately, immunosuppressive agents or other available treatments typically produce only short-term responses. Because of the lack of medical options after first-line therapy, the target population for this first study of anti-CD20 immunotherapy with hA20 are adult patients with chronic ITP who failed at least one standard ITP therapy (i.e., received at least one standard ITP therapy and now present with platelet levels below 30 x 109/L). In autoimmune disease, rituximab as well as other anti-CD20 antibodies currently being considered for commercialization have focused on a different dosing schedule in rheumatoid arthritis, and use fixed dosages rather than variable doses based on body surface area. In addition, recent studies of these newer anti-CD20 antibodies in rheumatoid arthritis have reported that lower doses indeed appear effective when administered twice, 2 weeks apart. Based upon these considerations, patients in this study will receive hA20 twice, 2 weeks apart, and administered at one of 3 dose levels.
Trial information was received from ClinicalTrials.gov and was last updated in March 2016.
Information provided to ClinicalTrials.gov by Immunomedics, Inc..